Condition: TNBC - Triple-Negative Breast Cancer · Sponsor: SURGE Therapeutics
This is a Phase 3 trial to compare SRG-514 (active pharmaceutical ingredient \[API\]: ketorolac) administered intraoperatively to the tumor resection cavity with standard-of-care (SOC) versus SOC alone in participants with clinical stage II-III triple negative breast cancer (TNBC) undergoing breast-conserving surgery (BCS) who are neoadjuvant therapy naïve.
This description comes directly from the study's public registry record.
Kayti Aviano · 781-605-8632 · kayti@surgetx.com
Always discuss trial participation with your own doctor first.
| Mayo | Rochester, Minnesota, United States | — |
| NYU Langone Health | New York, New York, United States | — |
| Duke Cancer Center | Durham, North Carolina, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07723469